Orgenesis Stock Analysis

ORGS -  USA Stock  

USD 5.12  0.34  7.11%

The modest gains experienced by current holders of Orgenesis may encourage retail investors to take a closer look at the company as it is trading at a share price of 5.12 on 66,800 in trading volume. The company directors and management have been quite successful in maneuvering the stock at opportune times to take advantage of all market conditions in June. The stock standard deviation of daily returns for 90 days investing horizon is currently 5.56. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Orgenesis partners.
Please check Your Equity Center.

Search Stock Analysis 

 
Refresh
The Orgenesis stock analysis report makes it easy to digest most publicly released information about Orgenesis and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Orgenesis Stock analysis module also helps to analyze the Orgenesis price relationship with some important fundamental indicators such as market cap and management efficiency.

Orgenesis Stock Analysis Notes

About 27.0% of the company shares are owned by institutional investors. The book value of Orgenesis was now reported as 2.23. The company recorded a loss per share of 2.79. Orgenesis had not issued any dividends in recent years. The entity had 35:1 split on the 16th of November 2017. Orgenesis Inc., a biotech company, focusing on cell and gene therapies . The company was incorporated in 2008 and is based in Germantown, Maryland. Orgenesis operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 111 people. To find out more about Orgenesis contact Scott Carmer at 480 659 6404 or learn more at http://www.orgenesis.com.

Orgenesis Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Orgenesis' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Orgenesis or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Orgenesis has very high historical volatility over the last 90 days
Orgenesis has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 15.16 M. Net Loss for the year was (83.17 M) with profit before overhead, payroll, taxes, and interest of 7.65 M.
Orgenesis currently holds about 41.84 M in cash with (68.9 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.71.
Latest headline from finance.yahoo.com: Would Shareholders Who Purchased Orgenesis Stock Three Years Be Happy With The Share price Today - Yahoo Finance

Orgenesis Upcoming and Recent Events

Earnings reports are used by Orgenesis to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Orgenesis previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report11th of October 2019
Next Earnings Report12th of February 2020
Next Fiscal Quarter End31st of August 2019
Next Fiscal Year End12th of February 2020
Last Quarter Report31st of May 2019
Last Earning Announcement31st of August 2018

Orgenesis SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Orgenesis prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Orgenesis investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Orgenesis specific information freely available to individual and institutional investors to make a timely investment decision.
1st of October 2020
Financial Statements and Exhibits. Regulation FD Disclosure. Unregistered Sales of Equity Securities. Entry into a Material Definitive Agreement
View

Orgenesis Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 117.01 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Orgenesis's market, we take the total number of its shares issued and multiply it by Orgenesis's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Management Efficiency

The entity has return on total asset (ROA) of (52.72) % which means that it has lost $52.72 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (122.25) %, meaning that it created substantial loss on money invested by shareholders. Orgenesis management efficiency ratios could be used to measure how well orgenesis manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 28th of July, Orgenesis holds the Semi Deviation of 4.08, risk adjusted performance of 0.0113, and Coefficient Of Variation of 28158.17. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Orgenesis, as well as the relationship between them. Put it differently, you can use this information to find out if the company will indeed mirror its model of past market data, or the prices will eventually revert. We were able to analyze and collect data for nineteen technical drivers for Orgenesis, which can be compared to its competitors. Please check Orgenesis downside deviation, jensen alpha, as well as the relationship between the Jensen Alpha and downside variance to decide if Orgenesis is priced some-what accurately, providing market reflects its current price of 5.12 per share. Given that Orgenesis has jensen alpha of (0.1), we recommend you to check out Orgenesis's recent market performance to make sure the company can sustain itself at a future point.

Orgenesis Price Movement Analysis

The output start index for this execution was thirty-five with a total number of output elements of twenty-six. The Triangular Moving Average shows Orgenesis double smoothed mean price over a specified number of previous prices (i.e., averaged twice). View also all equity analysis or get more info about triangular moving average overlap studies indicator.

Orgenesis Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Orgenesis insiders, such as employees or executives, is commonly permitted as long as it does not rely on Orgenesis' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Orgenesis insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Orgenesis Technical and Predictive Indicators

Orgenesis Forecast Models

Orgenesis time-series forecasting models is one of many Orgenesis' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Orgenesis' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Orgenesis Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Orgenesis stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Orgenesis shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Orgenesis. By using and applying Orgenesis Stock analysis, traders can create a robust methodology for identifying Orgenesis entry and exit points for their positions.
Orgenesis Inc., a biotech company, focusing on cell and gene therapies . The company was incorporated in 2008 and is based in Germantown, Maryland. Orgenesis operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 111 people.

Current Orgenesis Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Orgenesis analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Orgenesis analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
9.0Strong Buy1Odds
Orgenesis current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Orgenesis analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Orgenesis stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Orgenesis, talking to its executives and customers, or listening to Orgenesis conference calls.
Orgenesis Analyst Advice Details

Orgenesis Stock Analysis Indicators

Orgenesis stock analysis indicators help investors evaluate how Orgenesis stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Orgenesis shares will generate the highest return on investment. By understating and applying Orgenesis stock analysis, traders can identify Orgenesis position entry and exit signals to maximize returns.
Quick Ratio2.82
Fifty Two Week Low4.1400
Revenue Growth399.90%
Shares Short Prior Month1.57M
Average Daily Volume Last 10 Day60.07k
Average Daily Volume In Three Month478.67k
Shares Percent Shares Out7.46%
Gross Margins100.00%
Short Percent Of Float7.88%
Forward Price Earnings-7.97
Float Shares21.7M
Fifty Two Week High8.3000
Enterprise Value To Ebitda-1.17
Fifty Day Average4.9994
Two Hundred Day Average5.6796
Enterprise Value To Revenue6.79
Please check Your Equity Center. Note that the Orgenesis information on this page should be used as a complementary analysis to other Orgenesis' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Analyst Recommendations module to analyst recommendations and target price estimates broken down by several categories.

Complementary Tools for Orgenesis Stock analysis

When running Orgenesis price analysis, check to measure Orgenesis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Orgenesis is operating at the current time. Most of Orgenesis' value examination focuses on studying past and present price action to predict the probability of Orgenesis' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Orgenesis' price. Additionally, you may evaluate how the addition of Orgenesis to your portfolios can decrease your overall portfolio volatility.
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
The market value of Orgenesis is measured differently than its book value, which is the value of Orgenesis that is recorded on the company's balance sheet. Investors also form their own opinion of Orgenesis' value that differs from its market value or its book value, called intrinsic value, which is Orgenesis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Orgenesis' market value can be influenced by many factors that don't directly affect Orgenesis underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Orgenesis' value and its price as these two are different measures arrived at by different means. Investors typically determine Orgenesis value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Orgenesis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.